Answers are grounded in this paper and cite their sources.
Background/Objectives: In women with a type 3 transformation zone (TZ3), the squamocolumnar junction is not fully visible and endocervical disease may be missed. We assessed whether p16/Ki-67 dual-stain immunocytochemistry adds diagnostic information to HPV16/18 genotyping and liquid-based cytology. Methods: This single-center retrospective study included 312 HPV-positive women with colposcopically confirmed TZ3 who underwent cytology, dual staining and endocervical curettage (ECC) at one visit; ECC-detected CIN2+ was the reference standard. Nested logistic models (HPV16/18 plus cytology, with and without dual stain) were compared using the change in the area under the ROC curve (ΔAUC; AUC = probability that a woman with CIN2+ has a higher predicted risk than one without), a likelihood-ratio test and bootstrap internal validation. Results: ECC detected CIN2+ in 56 women (17.9%). Against ECC, dual-stain sensitivity was 82.1%, specificity 69.9% and negative predictive value 94.7%. Adding dual staining increased the AUC from 0.760 to 0.863 (ΔAUC 0.103, 95% CI 0.055–0.163; p < 0.001; optimism-corrected AUCs 0.751 and 0.855). Eight of ten dual-stain-negative CIN2+ cases had HPV16/18 and/or ASC-H/HSIL cytology. Conclusions: Dual staining improved statistical discrimination for ECC-detected CIN2+ beyond genotype and cytology. This does not establish clinical benefit; the test should not be used alone to omit ECC and requires external validation.
No takes yet. Share an insight, caveat, or question.
Alina-Elisabeta et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: